Trials / Conditions / Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis (SPMS)

10 registered clinical trials studyying Secondary Progressive Multiple Sclerosis (SPMS) — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Suspended	IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis NCT06677710	Indapta Therapeutics, INC.	Phase 1
Recruiting	Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis NCT07477639	Tr1X, Inc.	Phase 1 / Phase 2
Recruiting	A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis NCT07225504	Novartis Pharmaceuticals	Phase 3
Not Yet Recruiting	Study of NG01 Cell Therapy in Secondary Progressive Multiple Sclerosis NCT06961383	NeuroGenesis Ltd.	Phase 2
Recruiting	The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis NCT06599307	Cairo University	Phase 2
Withdrawn	Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS NCT03696485	Stem Cell Medicine Ltd.	Phase 1 / Phase 2
Completed	Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients NCT04593927	Novartis Pharmaceuticals	—
Recruiting	Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis NCT05177523	University Hospital, Basel, Switzerland	—
Completed	Multiple Sclerosis-Simvastatin Trial 2 NCT03387670	University College, London	Phase 3
Completed	Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion NCT01235455	Bayer	—